Sudhir Agrawal to Oligonucleotides
This is a "connection" page, showing publications Sudhir Agrawal has written about Oligonucleotides.
Connection Strength
3.861
-
Jiang W, Zhu FG, Bhagat L, Yu D, Tang JX, Kandimalla ER, La Monica N, Agrawal S. A Toll-like receptor 7, 8, and 9 antagonist inhibits Th1 and Th17 responses and inflammasome activation in a model of IL-23-induced psoriasis. J Invest Dermatol. 2013 Jul; 133(7):1777-84.
Score: 0.356
-
Bhagat L, Putta MR, Wang D, Yu D, Lan T, Jiang W, Sun Z, Wang H, Tang JX, La Monica N, Kandimalla ER, Agrawal S. Novel oligonucleotides containing two 3'-ends complementary to target mRNA show optimal gene-silencing activity. J Med Chem. 2011 Apr 28; 54(8):3027-36.
Score: 0.313
-
Yu D, Putta MR, Bhagat L, Li Y, Zhu F, Wang D, Tang JX, Kandimalla ER, Agrawal S. Agonists of Toll-like receptor 9 containing synthetic dinucleotide motifs. J Med Chem. 2007 Dec 13; 50(25):6411-8.
Score: 0.248
-
Li Y, Kandimalla ER, Yu D, Agrawal S. Oligodeoxynucleotides containing synthetic immunostimulatory motifs augment potent Th1 immune responses to HBsAg in mice. Int Immunopharmacol. 2005 Jun; 5(6):981-91.
Score: 0.209
-
Kandimalla ER, Bhagat L, Li Y, Yu D, Wang D, Cong YP, Song SS, Tang JX, Sullivan T, Agrawal S. Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists. Proc Natl Acad Sci U S A. 2005 May 10; 102(19):6925-30.
Score: 0.208
-
Wang D, Kandimalla ER, Yu D, Tang JX, Agrawal S. Oral administration of second-generation immunomodulatory oligonucleotides induces mucosal Th1 immune responses and adjuvant activity. Vaccine. 2005 Apr 08; 23(20):2614-22.
Score: 0.207
-
Wang D, Li Y, Yu D, Song SS, Kandimalla ER, Agrawal S. Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs. Int J Oncol. 2004 Apr; 24(4):901-8.
Score: 0.193
-
Agrawal S. Considerations for Creating the Next Generation of RNA Therapeutics: Oligonucleotide Chemistry and Innate Immune Responses to Nucleic Acids. Nucleic Acid Ther. 2024 04; 34(2):37-51.
Score: 0.193
-
Agrawal DK, Edwan J, Kandimalla ER, Yu D, Bhagat L, Wang D, Agrawal S. Novel immunomodulatory oligonucleotides prevent development of allergic airway inflammation and airway hyperresponsiveness in asthma. Int Immunopharmacol. 2004 Jan; 4(1):127-38.
Score: 0.190
-
Kandimalla ER, Bhagat L, Wang D, Yu D, Zhu FG, Tang J, Wang H, Huang P, Zhang R, Agrawal S. Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles. Nucleic Acids Res. 2003 May 01; 31(9):2393-400.
Score: 0.181
-
Yu D, Kandimalla ER, Zhao Q, Bhagat L, Cong Y, Agrawal S. Requirement of nucleobase proximal to CpG dinucleotide for immunostimulatory activity of synthetic CpG DNA. Bioorg Med Chem. 2003 Feb 06; 11(3):459-64.
Score: 0.178
-
Yu D, Kandimalla ER, Cong Y, Tang J, Tang JY, Zhao Q, Agrawal S. Design, synthesis, and immunostimulatory properties of CpG DNAs containing alkyl-linker substitutions: role of nucleosides in the flanking sequences. J Med Chem. 2002 Sep 26; 45(20):4540-8.
Score: 0.174
-
Yu D, Zhu FG, Bhagat L, Wang H, Kandimalla ER, Zhang R, Agrawal S. Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties. Biochem Biophys Res Commun. 2002 Sep 13; 297(1):83-90.
Score: 0.173
-
Gait MJ, Agrawal S. Introduction and History of the Chemistry of Nucleic Acids Therapeutics. Methods Mol Biol. 2022; 2434:3-31.
Score: 0.165
-
Agrawal S. RNA Therapeutics Are Stepping Out of the Maze. Trends Mol Med. 2020 12; 26(12):1061-1064.
Score: 0.151
-
Struthers M, Bett AJ, Wisniewski T, Dubey SA, Precopio M, Jiang W, Sun Z, Wang H, Nowak I, Putta MR, Yu D, Tang JX, Kandimalla ER, Agrawal S, Casimiro DR. Synthesis and immunological activities of novel agonists of toll-like receptor 9. Cell Immunol. 2010; 263(1):105-13.
Score: 0.073
-
Ebert CS, Rose AS, Blanks DA, Eapen RP, Kandimalla ER, Agrawal S, Prazma J, Pillsbury HC. Immune modulatory oligonucleotides in prevention of nasal allergen-induced Eustachian tube dysfunction in rats. Otolaryngol Head Neck Surg. 2007 Aug; 137(2):250-5.
Score: 0.061
-
Blanks DA, Ebert CS, Eapen RP, Zdanski C, Kandimalla ER, Agrawal S, Prazma J. Immune modulatory oligonucleotides in the prevention and treatment of OVA-induced eustachian tube dysfunction in rats. Otolaryngol Head Neck Surg. 2007 Aug; 137(2):321-6.
Score: 0.061
-
LaCasse EC, Cherton-Horvat GG, Hewitt KE, Jerome LJ, Morris SJ, Kandimalla ER, Yu D, Wang H, Wang W, Zhang R, Agrawal S, Gillard JW, Durkin JP. Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin Cancer Res. 2006 Sep 01; 12(17):5231-41.
Score: 0.057
-
Ebert CS, Rose AS, Patel MR, Hardy SM, Kandimalla ER, Agrawal S, Prazma J, Pillsbury HC. The role of immunomodulatory oligonucleotides in prevention of OVA-induced Eustachian tube dysfunction. Int J Pediatr Otorhinolaryngol. 2006 Dec; 70(12):2019-26.
Score: 0.057
-
Wang H, Rayburn ER, Wang W, Kandimalla ER, Agrawal S, Zhang R. Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy. Mol Cancer Ther. 2006 Aug; 5(8):2106-14.
Score: 0.057
-
Wang H, Rayburn ER, Wang W, Kandimalla ER, Agrawal S, Zhang R. Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9. Mol Cancer Ther. 2006 Jun; 5(6):1585-92.
Score: 0.056
-
Trabattoni D, Clivio A, Bray DH, Bhagat L, Beltrami S, Maffeis G, Cesana E, Lowry P, Lissoni F, Kandimalla ER, Sullivan T, Agrawal S, Bartholomew R, Clerici M. Immunization with gp120-depleted whole killed HIV immunogen and a second-generation CpG DNA elicits strong HIV-specific responses in mice. Vaccine. 2006 Feb 27; 24(9):1470-7.
Score: 0.053
-
Kandimalla ER, Bhagat L, Cong YP, Pandey RK, Yu D, Zhao Q, Agrawal S. Secondary structures in CpG oligonucleotides affect immunostimulatory activity. Biochem Biophys Res Commun. 2003 Jul 11; 306(4):948-53.
Score: 0.046
-
Kandimalla ER, Bhagat L, Yu D, Cong Y, Tang J, Agrawal S. Conjugation of ligands at the 5'-end of CpG DNA affects immunostimulatory activity. Bioconjug Chem. 2002 Sep-Oct; 13(5):966-74.
Score: 0.043
-
Agrawal S, Kandimalla ER, Yu D, Ball R, Lombardi G, Lucas T, Dexter DL, Hollister BA, Chen SF. GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts. Int J Oncol. 2002 Jul; 21(1):65-72.
Score: 0.043
-
Yu D, Kandimalla ER, Zhao Q, Cong Y, Agrawal S. Immunostimulatory properties of phosphorothioate CpG DNA containing both 3'-5'- and 2'-5'-internucleotide linkages. Nucleic Acids Res. 2002 Apr 01; 30(7):1613-9.
Score: 0.042
-
Conforti A, Cipriani B, Peruzzi D, Dharmapuri S, Kandimalla ER, Agrawal S, Mori F, Ciliberto G, La Monica N, Aurisicchio L. A TLR9 agonist enhances therapeutic effects of telomerase genetic vaccine. Vaccine. 2010 Apr 30; 28(20):3522-30.
Score: 0.018
-
Damiano V, Garofalo S, Rosa R, Bianco R, Caputo R, Gelardi T, Merola G, Racioppi L, Garbi C, Kandimalla ER, Agrawal S, Tortora G. A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action. Clin Cancer Res. 2009 Nov 15; 15(22):6921-30.
Score: 0.018
-
Damiano V, Caputo R, Garofalo S, Bianco R, Rosa R, Merola G, Gelardi T, Racioppi L, Fontanini G, De Placido S, Kandimalla ER, Agrawal S, Ciardiello F, Tortora G. TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. Proc Natl Acad Sci U S A. 2007 Jul 24; 104(30):12468-73.
Score: 0.015
-
Lacasse EC, Kandimalla ER, Winocour P, Sullivan T, Agrawal S, Gillard JW, Durkin J. Application of XIAP antisense to cancer and other proliferative disorders: development of AEG35156/ GEM640. Ann N Y Acad Sci. 2005 Nov; 1058:215-34.
Score: 0.013
-
Wang H, Hang J, Shi Z, Li M, Yu D, Kandimalla ER, Agrawal S, Zhang R. Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity. Int J Oncol. 2002 Jul; 21(1):73-80.
Score: 0.011